Dr Nathan Hill & Dr James Watson

MedInfomatics Ltd

Dr. Hill has specialised in clinical note software development over the last 10 years.

A passion for combining biology and computer technology together became apparent during an undergraduate study of a B.S.c in Biochemistry followed by an M.S.c in Computing at Cardiff University.

Dr Hill’s academic career culminated in a PhD Studentship at the Tenovus Centre for Cancer Research at the Welsh School of Pharmacy at Cardiff University.

More recently, Dr. Hill enjoys a senior leadership role at both OnICS Ltd, which has a US focus, and, more recently MedInfomatics Ltd through which the flagship iNOTZ clinical documentation product will be launched in the UK market in 2019.

Dr Hill is very proud to have been able to live in Cardiff all of his life whereby both OnICS and the core research and development activities of MedInfomatics are based at the Cardiff Medicentre, near the University Hospital of Wales.

Dr. Watson is a Clinical Oncologist who trained initially in Radiotherapy, then in Radiation Biology and has extensive experience in Medical Oncology and Brachytherapy where he developed surgical after-loading techniques for breast and head and neck cancers. In addition, he has considerable computing experience in a variety of languages having started programming when a medical student in 1962. He first embarked on the challenge of developing an electronic medical record and prescribing system in 1968 but his ambitions proved to be impracticable with the computers available to him at that time. He moved from the Middlesex Hospital and London University to Cambridge, UK, in 1975 with appointments as a Senior Clinical Scientist in the Medical Research Council Centre (MRC, including the Laboratory of Molecular Biology) and University of Cambridge, with consultant oncologist contracts in Addenbrooke's and Bedford Hospitals.

Dr. Watson has published extensively with over 250 peer-reviewed clinical and scientific papers and over 100 abstracts (stopped counting these after 100) in subjects as diverse as optics, statistics, computing (data analysis and multi¬ dimensional data handling and interpretation), clinical medicine, pathology, cell biology, biochemistry, and cytometry. He has written three books (two published by Cambridge University Press) and the third, A Guide to Understanding Cancer.

Dr. Watson founded Medinfomatics Ltd. in 2002 a company dedicated to cancer and health informatics and has developed novel user-friendly digital methods for clinical data capture at the point of care.

dont miss

Electronic Medical Records – have they lived up to expectations?

After two decades of electronic health records being rolled out across the globe, have they lived up to expectations versus original paper-based approaches?

As a result of the attempt to move away from paper to more ‘digital’ approaches, Dr Hill will explore how has this affected patient care, asking has it been beneficial to patients and health professionals or has it been a hindrance to their day to day work?


  • Dr Catherine Coyle: Speaking at the Oncology Convention

    Dr Catherine Coyle
    Christie Hospital NHS Foundation Trust

    Prostate Cancer- the non surgical oncologists view

  • Dr Khurum Khan: Speaking at the Oncology Convention

    Dr Khurum Khan
    University College London Hospitals

    Translational research in GI Oncology- how to make progress?

  • Professor Anthony Howell: Speaking at the Oncology Convention

    Professor Anthony Howell
    The University of Manchester / The Christie NHS Foundation Trust

    Improving risk estimation of breast cancer

  • Dr Abeer Shabaan: Speaking at the Oncology Convention

    Dr Abeer Shabaan
    Queen Elizabeth Hospital Birmingham & University of Birmingham

    Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations

  • Professor Noel Clarke: Speaking at the Oncology Convention

    Professor Noel Clarke
    The Christie and Salford Royal Hospitals, Manchester UK

    Improving Prostate Cancer Outcomes Through Cancer Trials